Biomark Diagnostics (FRA:20B) Current Deferred Taxes Liabilities: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:20B Biomark Diagnostics Inc FRA:20B
32 GF Score
Price €0.28
! 3 Warning Signs
View Full Analysis

What is Biomark Diagnostics Current Deferred Taxes Liabilities?

Biomark Diagnostics FRA:20B 32 Current Deferred Taxes Liabilities is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:20B with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Biomark Diagnostics's current deferred tax liabilities for the quarter that ended in Jun. 2026 was €0.00 Mil.

Biomark Diagnostics Current Deferred Taxes Liabilities Related Terms

Biomark Diagnostics Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics Current Deferred Taxes Liabilities Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biomark Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:20B
32GF Score
Biomark Diagnostics Inc FRA:20B
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of €0.00 Mil mean?
Biomark Diagnostics (FRA:20B) has a Current Deferred Taxes Liabilities of €0.00 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' Current Deferred Taxes Liabilities too high?
Biomark Diagnostics' current Current Deferred Taxes Liabilities is €0.00 Mil. Overall, Biomark Diagnostics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Current Deferred Taxes Liabilities compare to TMO and DHR?
Biomark Diagnostics' Current Deferred Taxes Liabilities of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Medical Diagnostics & Research company?
A good Current Deferred Taxes Liabilities depends on the Medical Diagnostics & Research industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current Current Deferred Taxes Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (FRA:20B) has a current Current Deferred Taxes Liabilities of €0.00 Mil. The current Current Deferred Taxes Liabilities is €0.00 Mil. Biomark Diagnostics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Biomark Diagnostics (FRA:20B), the current Current Deferred Taxes Liabilities is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
32GF Score

Get the complete analysis for FRA:20B

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.28
Price